Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension

Published 2019 View Full Article

Authors

Keywords

Heart failure with preserved ejection fraction (HFpEF), Pulmonary hypertension (PH), Pulmonary vascular resistance (PVR), Diastolic pressure gradient (DPG), Pulmonary artery compliance (PAC), Phosphodiesterase type 5 inhibitor (PDE5i)

Journal

INTERNATIONAL JOURNAL OF CARDIOLOGY

Volume -, Issue -, Pages -

Publisher

Elsevier BV

Online

2019-01-04

DOI

10.1016/j.ijcard.2018.12.078

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now